New trial of Genmab substance is symptomatic of Deborah Dunsire's Lundbeck
The study involving the Lu AF82422 antibody illustrates several of Lundbeck's recent tendencies, including attempts to ensure a higher study success rate and more substances in the company pipeline. This goes for both the approach to development and the variety of substances.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
The newly announced phase II trial with the substance Lu AF82422, which is part of a collaboration between Genmab and Lundbeck, is in many ways an example of the new research strategy that Lundbeck has created under the leadership of CEO Deborah Dunsire and Head of Research and Development Johan Luthman.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck ready to take Genmab antibody to phase II
For subscribers
